相关实验视频
Updated: Jul 26, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.9K
SGLT2 抑制剂对各种患者群体心血管结果的影响
Muhammad Shariq Usman1, Tariq Jamal Siddiqi1, Stefan D Anker2
1Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Journal of the American College of Cardiology
|June 21, 2023
概括
-葡萄糖共运输体-2 (SGLT2) 抑制剂显著减少心力衰竭 (HF) 事件和心血管 (CV) 死亡. 这些好处在患有2型糖尿病 (T2DM),高血压和慢性病 (CKD) 的患者中一致,单独或组合.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
背景情况:
- 关于SGLT2抑制剂对2型糖尿病 (T2DM),高血压和慢性病 (CKD) 患者心力衰竭 (HF) 和心血管 (CV) 死亡的影响存在不确定性.
- 这些情况往往并存,需要清楚地了解不同患者个人资料的治疗疗效.
研究的目的:
- 进行一项元分析,评估SGLT2抑制剂对HF结局和心血管死亡的影响.
- 评估T2DM,HF和CKD的各种组合对这些影响.
主要方法:
- 在2022年11月之前,对在线数据库进行了全面的搜索.
- 包含了13项涉及90,413名患者的试验,分析了首次HF住院 (HFH) 或心血管死亡,首次HFH和心血管死亡的复合结果.
- 数据使用随机效应模型进行聚合,以计算危险比率 (HR) 和95%置信区间 (CI).
主要成果:
- SGLT2抑制剂降低了首次HFH/CV死亡的风险,HF的24%,T2DM的23%,CKD的23%.
- 在各个子组中,这些益处是一致的,包括具有保留或减少喷射分数的高频率,以及T2DM和CKD的不同组合.
- 此外,SGLT2抑制剂还显著降低了心血管死亡率,在高血压中降低了16%,在T2DM中降低了15%,在CKD中降低了12%.
结论:
- SGLT2 抑制剂显示,HF 事件和心血管死亡的显著减少.
- 这些积极影响在所有患有HF,T2DM和CKD的患者群体中是一致的,无论疾病组合如何.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Glucose Transporters
23.3K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
210
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
210
Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Oral Hypoglycemic Agents: Glinides
189
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189

